Abstract

BackgroundThe true cost of treating Ankylosing Spondylitis (AS) comprises several elements including not only medication, but also healthcare resource utilization (HCRU), reduced work productivity, and absenteeism.ObjectivesWe report the results from...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.
Piercarlo Sarzi‐Puttini ... Nathan Vastesaeger
International journal of rheumatic diseases | VOL. 22
Piercarlo Sarzi‐Puttini, et. al.Piercarlo Sarzi‐Puttini ... Nathan Vastesaeger
15 Apr 2019
THU0513 Sustained Improvement in Health Related Quality of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated with Golimumab:5yr Results
C Han ... A Deodhar
Annals of the Rheumatic Diseases | VOL. 72
C Han, et. al.C Han ... A Deodhar
01 Jun 2013
Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany.
Klaus Krueger ... Sven Remstedt
Journal of comparative effectiveness research | VOL. 9
Klaus Krueger, et. al.Klaus Krueger ... Sven Remstedt
29 Jul 2020
SAT0393 Clinical and Quality of Life Improvements Observed with Golimumab and Infliximab in A Large Real-Life Ankylosing Spondylitis Population: Results from The Quo-Vadis Study
N Vastesaeger ... J Braun
Annals of the Rheumatic Diseases | VOL. 75
N Vastesaeger, et. al.N Vastesaeger ... J Braun
01 Jun 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations
Myrto Kostopoulou ... Antonis Fanouriakis
Annals of the Rheumatic Diseases | VOL. -
Myrto Kostopoulou, et. al.Myrto Kostopoulou ... Antonis Fanouriakis
22 May 2024
View more papers